11![Levodopa, dopamine agonist and COMT inhibitor products and the risk of impulse control disorders (ICDs) Final SmPC and PL wording agreed by PhVWP in July 2012 Doc.Ref.: CMDh/PhVWP[removed]July 2012 GREEN = new text Levodopa, dopamine agonist and COMT inhibitor products and the risk of impulse control disorders (ICDs) Final SmPC and PL wording agreed by PhVWP in July 2012 Doc.Ref.: CMDh/PhVWP[removed]July 2012 GREEN = new text](https://www.pdfsearch.io/img/c6fbdf82fe3a2baae1a2b4a6d69d546f.jpg) | Add to Reading ListSource URL: www.hma.euLanguage: English - Date: 2012-07-31 10:43:19
|
---|
12![SOGC CLINICAL PRACTICE GUIDELINE No. 315, November 2014 The Prevention of Ovarian Hyperstimulation Syndrome This clinical practice guideline has been prepared by the SOGC CLINICAL PRACTICE GUIDELINE No. 315, November 2014 The Prevention of Ovarian Hyperstimulation Syndrome This clinical practice guideline has been prepared by the](https://www.pdfsearch.io/img/fbbc716da713b5ea70c4474cb3fbbded.jpg) | Add to Reading ListSource URL: sogc.orgLanguage: English - Date: 2014-11-05 10:19:02
|
---|
13![Pharmacologically Induced/Exacerbated Restless Legs Syndrome, Periodic Limb Movements of Sleep, and REM Behavior Disorder/REM Sleep Without Atonia: Literature Review, Qualitative Scoring, and Comparative Analysis Romy Ho Pharmacologically Induced/Exacerbated Restless Legs Syndrome, Periodic Limb Movements of Sleep, and REM Behavior Disorder/REM Sleep Without Atonia: Literature Review, Qualitative Scoring, and Comparative Analysis Romy Ho](https://www.pdfsearch.io/img/99b508d1886b09b5ea057cdb1d621021.jpg) | Add to Reading ListSource URL: www.ihfglobal.comLanguage: English - Date: 2012-10-16 11:06:06
|
---|
14![Re-invigorating the Insecticide Discovery Pipeline for Vector Control: GPCRs as Targets for the Identification of Next Gen Insecticides Re-invigorating the Insecticide Discovery Pipeline for Vector Control: GPCRs as Targets for the Identification of Next Gen Insecticides](https://www.pdfsearch.io/img/5891a932d4d4597ebd206cbb98c5adf7.jpg) | Add to Reading ListSource URL: www.afpmb.orgLanguage: English - Date: 2013-03-25 21:23:06
|
---|
15![Imaging and Quantitation of Cannabinoid CB1 Receptors in Human and Monkey Brains Using 18F-Labeled Inverse Agonist Radioligands Garth E. Terry1,2, Jussi Hirvonen1, Jeih-San Liow1, Sami S. Zoghbi1, Robert Gladding1, Johan Imaging and Quantitation of Cannabinoid CB1 Receptors in Human and Monkey Brains Using 18F-Labeled Inverse Agonist Radioligands Garth E. Terry1,2, Jussi Hirvonen1, Jeih-San Liow1, Sami S. Zoghbi1, Robert Gladding1, Johan](https://www.pdfsearch.io/img/081d4b964c93edfacd36f3a87ab67732.jpg) | Add to Reading ListSource URL: intramural.nimh.nih.govLanguage: English - Date: 2010-05-25 11:38:04
|
---|
16![THE JOURNAL OF BIOLOGICAL CHEMISTRY © 2004 by The American Society for Biochemistry and Molecular Biology, Inc. Vol. 279, No. 1, Issue of January 2, pp. 686 –691, 2004 Printed in U.S.A. THE JOURNAL OF BIOLOGICAL CHEMISTRY © 2004 by The American Society for Biochemistry and Molecular Biology, Inc. Vol. 279, No. 1, Issue of January 2, pp. 686 –691, 2004 Printed in U.S.A.](https://www.pdfsearch.io/img/baa0c5ae214eee5912d96051608a3ed6.jpg) | Add to Reading ListSource URL: med.stanford.eduLanguage: English - Date: 2009-12-04 19:09:04
|
---|
17![DESCRIPTION DOSTINEX Tablets contain cabergoline, a dopamine receptor agonist. The chemical name for cabergoline is[removed]allylergolin-8ß-yl)-carbonyl[removed]dimethylamino) propyl]-3-ethylurea. Its empirical formula is DESCRIPTION DOSTINEX Tablets contain cabergoline, a dopamine receptor agonist. The chemical name for cabergoline is[removed]allylergolin-8ß-yl)-carbonyl[removed]dimethylamino) propyl]-3-ethylurea. Its empirical formula is](https://www.pdfsearch.io/img/64734f94e85da2319f0bc29e5f7af4fa.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-08-12 14:47:04
|
---|
18![FDA Approved Labeling Text for NDA[removed]Dated[removed]mg/mL For Subcutaneous Use Only FDA Approved Labeling Text for NDA[removed]Dated[removed]mg/mL For Subcutaneous Use Only](https://www.pdfsearch.io/img/f47166534c83386d1ac71e324811d9f2.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2010-09-07 12:18:07
|
---|
19![This is a post-print version of an original article which has been peer reviewed and accepted by International Musculoskeletal Medicine [ www.maney.co.uk ] and is now in-press with a publication date in[removed]The proto
This is a post-print version of an original article which has been peer reviewed and accepted by International Musculoskeletal Medicine [ www.maney.co.uk ] and is now in-press with a publication date in[removed]The proto](https://www.pdfsearch.io/img/7e13064089a805db1b622248c176e5f1.jpg) | Add to Reading ListSource URL: www.lcom.org.ukLanguage: English - Date: 2012-09-11 17:44:25
|
---|
20![10 mg/mL For Subcutaneous Use Only Not for IV Use Rx only DESCRIPTION: APOKYN® (apomorphine hydrochloride, USP) is a non-ergoline dopamine agonist. Apomorphine hydrochloride is chemically designated as 6aβ-Aporphine-10 10 mg/mL For Subcutaneous Use Only Not for IV Use Rx only DESCRIPTION: APOKYN® (apomorphine hydrochloride, USP) is a non-ergoline dopamine agonist. Apomorphine hydrochloride is chemically designated as 6aβ-Aporphine-10](https://www.pdfsearch.io/img/1b4d518483745c982781ad31650b3dab.jpg) | Add to Reading ListSource URL: www.apokyn.comLanguage: English - Date: 2012-09-19 15:26:02
|
---|